Abstract
A scheme of synthesis of previously obtained RGDF-peptidomimetic-4-oxo-4-(piperazine-1-yl)butyrylglycyl-D,L-beta-phenyl-beta-alanine (I), was simplified. The novel RGDF-peptidomimetic -4-oxo-4-piperazine-1-yl)butyryl-glycyl-L-aspartyl-L-phenylalanine (II) was synthesized with the use of 4-oxo-4-(piperazine-1-yl)butyric acid as arginyl mimetic. The obtained pseudopeptides were able to inhibit both platelet aggregation in human blood and binding of fibrinogen to its receptor.
MeSH terms
-
Blood Platelets / metabolism
-
Chemistry, Pharmaceutical
-
Fibrinogen / metabolism
-
Humans
-
In Vitro Techniques
-
Molecular Mimicry
-
Oligopeptides / chemical synthesis*
-
Oligopeptides / chemistry*
-
Oligopeptides / pharmacology
-
Piperazines / chemical synthesis*
-
Piperazines / chemistry
-
Piperazines / pharmacology
-
Platelet Aggregation Inhibitors / chemical synthesis*
-
Platelet Aggregation Inhibitors / chemistry
-
Platelet Aggregation Inhibitors / pharmacology
-
Protein Binding
Substances
-
4-oxo-4-(piperazine-1-yl)butyryl-glycyl-L-aspartyl-L-phenylalanine
-
Oligopeptides
-
Piperazines
-
Platelet Aggregation Inhibitors
-
arginyl-glycyl-aspartic acid
-
Fibrinogen